High Quality API CAS 2022-85-7 Flucytosine/Fluorocytosine

Apis, commonly referred to as chemical apis, are active ingredients in chemical pharmaceutical preparations. China is the world's largest API producer and exporter. With the improvement of environmental protection and product quality requirements for API enterprises at the policy end, low-end production capacity continues to clear, the concentration of API industry increases, and competition among high-quality API enterprises tends to be fierce.
In recent years, influenced by multiple factors on the policy side and the demand side, the business model of domestic API enterprises has undergone obvious and profound changes.
From the policy point of view, in the context of green development and improved product quality requirements, API companies are facing more stringent environmental requirements and production standards, which has significantly increased the entry threshold of the API industry. At the same time, because the quality of API will directly affect the results of the consistency evaluation of generic drug quality and efficacy, pharmaceutical enterprises pay more attention to the quality control of API suppliers, and the cooperation between pharmaceutical enterprises and associated approved API suppliers gradually becomes stable. The customer orders of low-end API enterprises continue to lose, and low-end production capacity is gradually cleared. The concentration of the API industry has been further improved, the product overlap of high-quality API enterprises has increased, and the competition has become fierce.
From the perspective of demand, opportunities such as capacity transfer, product localization of multinational enterprises, normalized centralized procurement with volume and vigorous development of innovative drug market provide different development ideas for API enterprises: first, continue to focus on the field of API, expand product pipeline, increase production capacity, reduce cost and increase efficiency; The second is to cut into the downstream preparation market to take advantage of cost advantages and volume collection opportunities, and enter the local collection market; Third, by virtue of their own large-scale production experience and cost control ability in the production end, improve the ability of research and development end, and develop CDMO business.